Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand

American Journal of Hematology

Volumn 88, Issue 4, 2013, Pages 251-260

  Viprakasit, Vip ^a   Nuchprayoon, Issarang ^b   Chuansumrit, Ampaiwan ^c   Torcharus, Kitti ^d   Pongtanakul, Bunchoo ^a   Laothamatas, Jiraporn ^c   Srichairatanakool, Somdet ^e   Pooliam, Julaporn ^a   Supajitkasem, Siriwat ^a   Suriyaphol, Prapat ^a   Tanphaichitr, Voravarn S ^a,f   Tuchinda, Soodsarkorn ^f  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^e Faculty of Medicine Chiang Mai University   (Thailand)

^f Thalassemia Foundation of Thailand (TFT)   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; FERRITIN; IRON;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVERSE OUTCOME; ANEMIA; ARTICLE; BETA THALASSEMIA; CHILD; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; FERRITIN BLOOD LEVEL; GROWTH DISORDER; HEARING IMPAIRMENT; HUMAN; HYPERTRANSAMINASEMIA; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; PROSPECTIVE STUDIES; PYRIDONES; THAILAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875619524     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23386     Document Type: Article

References (59)

1. Piga A, Longo F, Voi V, et al. Late effects of bone marrow transplantation for thalassemia. Ann N Y Acad Sci 1998;850:294-299.
2. Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for beta-thalassemia major. Blood 2011;117:1745-1750.
3. Viprakasit V, Tanphaichitr VS, Mahasandana C, et al. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens. J Med Assoc Thai 2001;84:929-941.
4. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
5. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
6. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-252.
7. Cappellini MD, Piga A. Current status in iron chelation in hemoglobinopathies. Curr Mol Med 2008;8:663-674.
8. Weatherall DJ. Thalassemia as a global health problem: Recent progress toward its control in the developing countries. Ann N Y Acad Sci 2010;1202:17-23.
9. Viprakasit V, Gattermann N, Lee JW, et al. Geographical differences in transfusion and iron chelation practices in 1558 patients with transfusion-dependent anemias. Blood Transfus 2012;12:1-14.
10. Kusuwan T, Pangnukroh L, Leekamnerdthai W, et al. Analysis of treatment complicance and related health and social determining factors in thai thalassemia patients under long-term deferrioxamine administration. Siriraj Nursing J 2008;2:1-14.
11. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995;332:918-922.
12. Saiviroonporn P, Viprakasit V, Kleebsabai S, et al. Inter-Site validations of the pixel-wise method for liver R2* analysis in transfusion-dependent Thai Thalassemia patients. J Med Assoc Thai 2012;95(Suppl 2):S165-S172.
13. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
14. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000;110:971-977.
15. Sobota A, Yamashita R, Xu Y, et al. Quality of life in thalassemia: A comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol 2011;86:92-95.
16. Viprakasit V, Lee-Lee C, Chong QT, et al. Iron chelation therapy in the management of thalassemia: The Asian perspectives. Int J Hematol 2009;90:435-445.
17. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-917.
18. Trachtenberg F, Vichinsky E, Haines D, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol 2011;86:433-436.
19. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up. Blood 2011;118:884-893.
20. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-423.
21. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587.
22. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100:1566-1569.
23. Limenta LM, Jirasomprasert T, Tankanitlert J, et al. UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol 2008;65:908-916.
24. Morales NP, Yamanont P, Jirasomprasert T, et al. Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers. Int J Clin Pharmacol Ther 2009;47:358-364.
25. Limenta LM, Jirasomprasert T, Jittangprasert P, et al. Pharmacokinetics of deferiprone in patients with beta-thalassaemia: Impact of splenectomy and iron status. Clin Pharmacokinet 2011;50:41-50.
26. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin-bound iron. Anal Biochem 1990;186:320-323.
27. Kirk P, He T, Anderson LJ, et al. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging 2010;32:315-319.
28. Sripornsawan P, Pongtanakul B, Viprakrasit V. Prospective clinical evaluation for serious adverse events and complications due to deferiprone (L-1) in Thai pediatric patients. Proceeding of the XXXII World Congress of the International Society of Hematology (ISH); Journal of Hematology and Blood Transfusion; 2008; Bangkok, Thailand: Thai Society of Hematology; 2008. p. 33.
29. Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009;113:4853-4855.
30. Detterich J, Noetzli L, Dorey F, et al. Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am J Hematol 2012;87:139-144.
31. Porter JB, Shah FT. Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am 2010;24:1109-1130.
32. Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica 2003;88:489-496.
33. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-3737.
34. Maggio A, Vitrano A, Lucania G, et al. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients. Am J Hematol 2012;87:732-733.
35. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
36. al-Refaie FN, Wonke B, Hoffbrand AV, et al. Efficacy and possible adverse effects of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992;80:593-599.
37. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460-466.
38. Hoffbrand AV, F AL-R, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
39. Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: A multicentre study. Br J Haematol 2000;108:305-312.
40. Choudhry VP, Pati HP, Saxena A, et al. Deferiprone, efficacy and safety. Indian J Pediatr 2004;71:213-216.
41. Ha SY, Chik KW, Ling SC, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin 2006;30:263-274.
42. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-336.
43. Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: Application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003;121:938-948.
44. Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 2007;92:1599-1606.
45. Roberts DJ, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007;18:CD004839.
46. Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis 2011;47:166-175.
47. Cappellini MD, Cohen A, Eleftheriou A, et al. Iron Overload. Guidlines for the Clinical Management of Thalassemia. Nicosia, Cyprus: Thalassemia International Federation; 2007, Chapter 3. pp 31-63.
48. Angelucci E, Barosi G, Camaschella C, et al. Italian society of hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93:741-752.
49. Ho PJ, Tay L, Lindeman R, et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J 2011;41:516-524.
50. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm.
51. Berdoukas V, Farmaki K, Wood JC, et al. Iron chelation in thalassemia: Time to reconsider our comfort zones. Expert Rev Hematol 2011;4:17-26.
52. Farmaki K, Tzoumari I, Pappa C, et al. Normalization of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010;148:466-475.
53. Taher A, Chamoun FM, Koussa S, et al. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol 1999;101:173-177.
54. Hoffbrand AV. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol 2005;18:299-317.
55. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-364.
56. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis 2011;47:33-40.
57. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol 2005;74:217-220.
58. ElAlfy MS, Sari TT, Lee CL, et al. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol 2010;32:601-605.
59. Peng CT, Chow KC, Chen JH, et al. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003;70:392-397.